Pulmonary Hypertension in Heart Failure

Journal of Cardiac Failure

Volumn 16, Issue 6, 2010, Pages 461-474

  Guglin, Maya ^a   Khan, Hammad ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Heart failure, pulmonary hypertension; heart transplant; left ventricular assist device; pulmonary reversibility testing; pulmonary vascular resistance

Indexed keywords

BOSENTAN; DARUSENTAN; DIPYRIDAMOLE; DOBUTAMINE; DOPAMINE; ENOXIMONE; GLYCERYL TRINITRATE; ILOPROST; MILRINONE; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROSTACYCLIN; PROSTAGLANDIN E1; SILDENAFIL; SITAXSENTAN; TEZOSENTAN;

AMINOTRANSFERASE BLOOD LEVEL; BOLUS INJECTION; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL TRIAL; DEATH; DEVICE THERAPY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEADACHE; HEART ASSIST DEVICE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART OUTPUT; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOTENSION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG EDEMA; LUNG VASCULAR RESISTANCE; METHEMOGLOBINEMIA; MORTALITY; NAUSEA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SIDE EFFECT; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOTONIC AGENTS; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; RISK FACTORS; STROKE VOLUME; VASCULAR RESISTANCE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 77953610725     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2010.01.003     Document Type: Review

References (159)

1. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53 (2009) 1573-1619
2. Abramson S.V., Burke J.F., Kelly Jr. J.J., et al. Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy. Ann Intern Med 116 (1992) 888-895
3. Ghio S., Gavazzi A., Campana C., et al. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 37 (2001) 183-188
4. Lam C.S., Roger V.L., Rodeheffer R.J., Borlaug B.A., Enders F.T., and Redfield M.M. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53 (2009) 1119-1126
5. Barst R.J., McGoon M., Torbicki A., et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 40S-47S
6. Roldan C. The ultimate echo guide (2005), Lippincott Williams and Wilkins, Philadelphia, PA
7. Hoeper M.M., Barbera J.A., Channick R.N., et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 54 (2009) S85-S96
8. Drazner M.H., Hamilton M.A., Fonarow G., Creaser J., Flavell C., and Stevenson L.W. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 18 (1999) 1126-1132
9. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106 (2002) 92-99
10. Fan T.H., Liang C.S., Kawashima S., and Banerjee S.P. Alterations in cardiac beta-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol 140 (1987) 123-132
11. Kiely D.G., Cargill R.I., and Lipworth B.J. Angiotensin II receptor blockade and effects on pulmonary hemodynamics and hypoxic pulmonary vasoconstriction in humans. Chest 110 (1996) 698-703
12. Haddad F., Doyle R., Murphy D.J., and Hunt S.A. Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure. Circulation 117 (2008) 1717-1731
13. Huang W., Kingsbury M.P., Turner M.A., Donnelly J.L., Flores N.A., and Sheridan D.J. Capillary filtration is reduced in lungs adapted to chronic heart failure: morphological and haemodynamic correlates. Cardiovasc Res 49 (2001) 207-217
14. Rich S., and Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation 118 (2008) 2190-2199
15. Enriquez-Sarano M., Rossi A., Seward J.B., Bailey K.R., and Tajik A.J. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 29 (1997) 153-159
16. Tribouilloy C.M., Enriquez-Sarano M., Rossi A., Tajik A.J., and Seward J.B. Determinants of the pulmonary artery pressure rise in left ventricular dysfunction. Cardiologia 42 (1997) 1051-1058
17. Capomolla S., Febo O., Guazzotti G., et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant 19 (2000) 426-438
18. Faggiano P., Antonini-Canterin F., Ribichini F., et al. Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis. Am J Cardiol 85 (2000) 204-208
19. Dini F.L., Nuti R., Barsotti L., Baldini U., Dell'Anna R., and Micheli G. Doppler-derived mitral and pulmonary venous flow variables are predictors of pulmonary hypertension in dilated cardiomyopathy. Echocardiography 19 (2002) 457-465
20. Stein J.H., Neumann A., Preston L.M., et al. Echocardiography for hemodynamic assessment of patients with advanced heart failure and potential heart transplant recipients. J Am Coll Cardiol 30 (1997) 1765-1772
21. Straburzynska-Migaj E., Szyszka A., Trojnarska O., and Cieslinski A. Restrictive filling pattern predicts pulmonary hypertension and is associated with increased BNP levels and impaired exercise capacity in patients with heart failure. Kardiol Pol 65 (2007) 1049-1055 discussion 1056-7
22. Neuman Y., Kotliroff A., Bental T., Siegel R.J., David D., and Lishner M. Pulmonary artery pressure and diastolic dysfunction in normal left ventricular systolic function. Int J Cardiol 127 (2008) 174-178
23. Robbins I.M., Newman J.H., Johnson R.F., et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 136 (2009) 3-4
24. Abdelwhab S., and Elshinnawy S. Pulmonary hypertension in chronic renal failure patients. Am J Nephrol 28 (2008) 990-997
25. Franciosa J.A., Baker B.J., and Seth L. Pulmonary versus systemic hemodynamics in determining exercise capacity of patients with chronic left ventricular failure. Am Heart J 110 (1985) 807-813
26. Tumminello G., Lancellotti P., Lempereur M., D'Orio V., and Pierard L.A. Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 28 (2007) 569-574
27. Cappola T.P., Felker G.M., Kao W.H., Hare J.M., Baughman K.L., and Kasper E.K. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 105 (2002) 1663-1668
28. Kjaergaard J., Akkan D., Iversen K.K., et al. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol 99 (2007) 1146-1150
29. Lam C.S., Borlaug B.A., Kane G.C., Enders F.T., Rodeheffer R.J., and Redfield M.M. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 119 (2009) 2663-2670
30. Shalaby A., Voigt A., El-Saed A., and Saba S. Usefulness of pulmonary artery pressure by echocardiography to predict outcome in patients receiving cardiac resynchronization therapy heart failure. Am J Cardiol 101 (2008) 238-241
31. Butler J., Chomsky D.B., and Wilson J.R. Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 34 (1999) 1802-1806
32. Stobierska-Dzierzek B., Awad H., and Michler R.E. The evolving management of acute right-sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 38 (2001) 923-931
33. Erickson K.W., Costanzo-Nordin M.R., O'Sullivan E.J., et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 9 (1990) 526-537
34. Chen J.M., Levin H.R., Michler R.E., Prusmack C.J., Rose E.A., and Aaronson K.D. Reevaluating the significance of pulmonary hypertension before cardiac transplantation: determination of optimal thresholds and quantification of the effect of reversibility on perioperative mortality. J Thorac Cardiovasc Surg 114 (1997) 627-634
35. Delgado J.F., Gomez-Sanchez M.A., Saenz de la Calzada C., et al. Impact of mild pulmonary hypertension on mortality and pulmonary artery pressure profile after heart transplantation. J Heart Lung Transplant 20 (2001) 942-948
36. Mehra M.R., Kobashigawa J., Starling R., et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates-2006. J Heart Lung Transplant 25 (2006) 1024-1042
37. Gorlitzer M., Ankersmit J., Fiegl N., et al. Is the transpulmonary pressure gradient a predictor for mortality after orthotopic cardiac transplantation?. Transpl Int 18 (2005) 390-395
38. Butler J., Stankewicz M.A., Wu J., et al. Pre-transplant reversible pulmonary hypertension predicts higher risk for mortality after cardiac transplantation. J Heart Lung Transplant 24 (2005) 170-177
39. Tenderich G., Koerner M.M., Stuettgen B., et al. Does preexisting elevated pulmonary vascular resistance (transpulmonary gradient > 15 mm Hg or > 5 wood) predict early and long-term results after orthotopic heart transplantation?. Transplant Proc 30 (1998) 1130-1131
40. Tenderich G., Koerner M.M., Stuettgen B., et al. Pre-existing elevated pulmonary vascular resistance: long-term hemodynamic follow-up and outcome of recipients after orthotopic heart transplantation. J Cardiovasc Surg (Torino) 41 (2000) 215-219
41. Addonizio L.J., Gersony W.M., Robbins R.C., et al. Elevated pulmonary vascular resistance and cardiac transplantation. Circulation 76 (1987) V52-V55
42. Klotz S., Deng M.C., Hanafy D., et al. Reversible pulmonary hypertension in heart transplant candidates-pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 5 (2003) 645-653
43. Lindelow B., Andersson B., Waagstein F., and Bergh C.H. High and low pulmonary vascular resistance in heart transplant candidates. A 5-year follow-up after heart transplantation shows continuous reduction in resistance and no difference in complication rate. Eur Heart J 20 (1999) 148-156
44. Bhatia S.J., Kirshenbaum J.M., Shemin R.J., et al. Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Circulation 76 (1987) 819-826
45. Chau E.M., Bailey K.R., Mahoney D.W., et al. Predictors of reversibility of pulmonary hypertension in cardiac transplant recipients in the first postoperative year. Circulation 94 (1996) II267-II272
46. Costard-Jackle A., and Fowler M.B. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 19 (1992) 48-54
47. Gavazzi A., Ghio S., Scelsi L., et al. Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 145 (2003) 310-316
48. Givertz M.M., Hare J.M., Loh E., Gauthier D.F., and Colucci W.S. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 28 (1996) 1775-1780
49. Pamboukian S.V., Carere R.G., Webb J.G., et al. The use of milrinone in pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. J Heart Lung Transplant 18 (1999) 367-371
50. Sablotzki A., Starzmann W., Scheubel R., Grond S., and Czeslick E.G. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can J Anaesth 52 (2005) 1076-1082
51. Kieler-Jensen N., Ricksten S.E., Stenqvist O., et al. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. J Heart Lung Transplant 13 (1994) 366-375
52. Balzer D.T., Kort H.W., Day R.W., et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation 106 (2002) I76-I81
53. Semigran M.J., Cockrill B.A., Kacmarek R., et al. Hemodynamic effects of inhaled nitric oxide in heart failure. J Am Coll Cardiol 24 (1994) 982-988
54. Lepore J.J., Dec G.W., Zapol W.M., Bloch K.D., and Semigran M.J. Combined administration of intravenous dipyridamole and inhaled nitric oxide to assess reversibility of pulmonary arterial hypertension in potential cardiac transplant recipients. J Heart Lung Transplant 24 (2005) 1950-1956
55. Haraldsson A., Kieler-Jensen N., and Ricksten S.E. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacodynamic study. J Cardiothorac Vasc Anesth 10 (1996) 864-868
56. Montalescot G., Drobinski G., Meurin P., et al. Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 82 (1998) 749-755
57. von Scheidt W., Costard-Jaeckle A., Stempfle H.U., et al. Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 25 (2006) 1070-1076
58. Klotz S., Wenzelburger F., Stypmann J., et al. Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. Ann Thorac Surg 82 (2006) 1770-1773
59. Kieler-Jensen N., Houltz E., and Ricksten S.E. A comparison of prostacyclin and sodium nitroprusside for the treatment of heart failure after cardiac surgery. J Cardiothorac Vasc Anesth 9 (1995) 641-646
60. Weston M.W., Isaac B.F., and Crain C. The use of inhaled prostacyclin in nitroprusside-resistant pulmonary artery hypertension. J Heart Lung Transplant 20 (2001) 1340-1344
61. Sablotzki A., Hentschel T., Gruenig E., et al. Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance. Eur J Cardiothorac Surg 22 (2002) 746-752
62. Haraldsson A., Kieler-Jensen N., Nathorst-Westfelt U., Bergh C.H., and Ricksten S.E. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest 114 (1998) 780-786
63. Radovancevic B., Vrtovec B., Thomas C.D., et al. Nitric oxide versus prostaglandin E1 for reduction of pulmonary hypertension in heart transplant candidates. J Heart Lung Transplant 24 (2005) 690-695
64. Murali S., Uretsky B.F., Reddy P.S., Tokarczyk T.R., and Betschart A.R. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: comparative effects of various pharmacologic agents. Am Heart J 122 (1991) 1375-1381
65. Torres Macho J., Delgado Jimenez J.F., Sanz Salvo J., et al. Effect of different pharmacologic agents to reverse severe pulmonary hypertension among end-stage heart failure patients. Transplant Proc 41 (2009) 2477-2479
66. Alaeddini J., Uber P.A., Park M.H., Scott R.L., Ventura H.O., and Mehra M.R. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94 (2004) 1475-1477
67. Angel Gomez-Sanchez M., Saenz De La Calzada C., Escribano Subias P., et al. Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail 6 (2004) 615-617
68. Botha P., Parry G., Dark J.H., and Macgowan G.A. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. J Heart Lung Transplant 28 (2009) 676-682
69. Crilley J.G., Dark J.H., and Hall J.A. Reversal of severe pulmonary hypertension with beta blockade in a patient with end stage left ventricular failure. Heart 80 (1998) 620-622
70. Healey J.S., Davies R.A., and Tang A.S. Improvement of apparently fixed pulmonary hypertension with cardiac resynchronization therapy. J Heart Lung Transplant 23 (2004) 650-652
71. Katz S.D., Balidemaj K., Homma S., Wu H., Wang J., and Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36 (2000) 845-851
72. Forfia P.R., Lee M., Tunin R.S., Mahmud M., Champion H.C., and Kass D.A. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol 49 (2007) 1079-1088
73. Guazzi M. Sildenafil and phosphodiesterase-5 inhibitors for heart failure. Curr Heart Fail Rep 5 (2008) 110-114
74. Das A., Xi L., and Kukreja R.C. Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280 (2005) 12944-12955
75. Fisher P.W., Salloum F., Das A., Hyder H., and Kukreja R.C. Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111 (2005) 1601-1610
76. Patel M.D., and Katz S.D. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension. Am J Cardiol 96 (2005) 47M-51M
77. Guazzi M., Arena R., Pinkstaff S., and Guazzi M.D. Six months of Sildenafil therapy improves heart rate recovery in patients with heart failure. Int J Cardiol 136 (2008) 141-143
78. Hirata K., Adji A., Vlachopoulos C., and O'Rourke M.F. Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 96 (2005) 1436-1440
79. Borlaug B.A., Melenovsky V., Marhin T., Fitzgerald P., and Kass D.A. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. Circulation 112 (2005) 2642-2649
80. Lewis G.D., Lachmann J., Camuso J., et al. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 115 (2007) 59-66
81. Jabbour A., Keogh A., Hayward C., and Macdonald P. Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. Eur J Heart Fail 9 (2007) 674-677
82. Guazzi M., Tumminello G., Di Marco F., and Guazzi M.D. Influences of sildenafil on lung function and hemodynamics in patients with chronic heart failure. Clin Pharmacol Ther 76 (2004) 371-378
83. Lepore J.J., Maroo A., Bigatello L.M., et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 127 (2005) 1647-1653
84. Guazzi M., Casali M., Berti F., Rossoni G., Colonna V.D., and Guazzi M.D. Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients. Clin Pharmacol Ther 83 (2008) 336-341
85. Guazzi M., Samaja M., Arena R., Vicenzi M., and Guazzi M.D. Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50 (2007) 2136-2144
86. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 116 (2007) 1555-1562
87. Herrmann H.C., Chang G., Klugherz B.D., and Mahoney P.D. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 342 (2000) 1622-1626
88. Behling A., Rohde L.E., Colombo F.C., Goldraich L.A., Stein R., and Clausell N. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. J Card Fail 14 (2008) 189-197
89. Zakliczynski M., Maruszewski M., Pyka L., et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc 39 (2007) 2856-2858
90. Maruszewski M., Zakliczynski M., Przybylski R., Kucewicz-Czech E., and Zembala M. Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure. Transplant Proc 39 (2007) 2850-2852
91. Klodell Jr. C.T., Morey T.E., Lobato E.B., et al. Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 83 (2007) 68-71 discussion 71
92. Kieler-Jensen N., Lundin S., and Ricksten S.E. Vasodilator therapy after heart transplantation: effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E1, and sodium nitroprusside. J Heart Lung Transplant 14 (1995) 436-443
93. Califf R.M., Adams K.F., McKenna W.J., et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 134 (1997) 44-54
94. Hulsmann M., Stanek B., Frey B., et al. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure. J Heart Lung Transplant 16 (1997) 556-562
95. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in congestive heart failure. Circulation 77 (1988) I64-I73
96. Yui Y., Nakajima H., Kawai C., and Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 50 (1982) 320-324
97. Serra W., Musiari L., Ardissino D., Gherli T., and Montanari A. Benefit of prostaglandin infusion in severe heart failure Preliminary clinical experience of repetitive administration. Int J Cardiol (2009)
98. Sueta C.A., Gheorghiade M., Adams Jr. K.F., et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Epoprostenol Multicenter Research Group. Am J Cardiol 75 (1995) 34A-43A
99. Wittwer T., Pethig K., Struber M., et al. Aerosolized iloprost for severe pulmonary hypertension as a bridge to heart transplantation. Ann Thorac Surg 71 (2001) 1004-1006
100. Stanek B., Sturm B., Frey B., et al. Bridging to heart transplantation: prostaglandin E1 versus prostacyclin versus dobutamine. J Heart Lung Transplant 18 (1999) 358-366
101. Langer F., Wendler O., Wilhelm W., Tscholl D., and Schafers H.J. Treatment of a case of acute right heart failure by inhalation of iloprost, a long-acting prostacyclin analogue. Eur J Anaesthesiol 18 (2001) 770-773
102. Porter T.R., Taylor D.O., Cycan A., et al. Endothelium-dependent pulmonary artery responses in chronic heart failure: influence of pulmonary hypertension. J Am Coll Cardiol 22 (1993) 1418-1424
103. Cooper C.J., Jevnikar F.W., Walsh T., Dickinson J., Mouhaffel A., and Selwyn A.P. The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure. Am J Cardiol 82 (1998) 609-614
104. Stewart D.J., Cernacek P., Costello K.B., and Rouleau J.L. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85 (1992) 510-517
105. Lucas M., Jasmin J.F., and Dupuis J. Effect of ET(A) receptor antagonist on pulmonary hypertension and vascular reactivity in rats with congestive heart failure. Pulm Pharmacol Ther 14 (2001) 307-314
106. Cody R.J., Haas G.J., Binkley P.F., Capers Q., and Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85 (1992) 504-509
107. Sutsch G., Kiowski W., Yan X.W., et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 98 (1998) 2262-2268
108. Kiowski W., Sutsch G., Oechslin E., and Bertel O. Hemodynamic effects of bosentan in patients with chronic heart failure. Heart Fail Rev 6 (2001) 325-334
109. Anand I., McMurray J., Cohn J.N., et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 347-354
110. Kaluski E., Cotter G., Leitman M., et al. Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension-a multi-center randomized study. Cardiology 109 (2008) 273-280
111. Kalra P.R., Moon J.C., and Coats A.J. Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?. Int J Cardiol 85 (2002) 195-197
112. Luscher T.F., Enseleit F., Pacher R., et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 106 (2002) 2666-2672
113. McMurray J.J., Teerlink J.R., Cotter G., et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298 (2007) 2009-2019
114. Packer M., McMurray J., Massie B.M., et al. Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study. J Card Fail 11 (2005) 12-20
115. Perez-Villa F., Cuppoletti A., Rossel V., Vallejos I., and Roig E. Initial experience with bosentan therapy in patients considered ineligible for heart transplantation because of severe pulmonary hypertension. Clin Transplant 20 (2006) 239-244
116. Fagan K.A., Tyler R.C., Sato K., et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am J Physiol 277 (1999) L472-L478
117. Cooper C.J., Landzberg M.J., Anderson T.J., et al. Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. Circulation 93 (1996) 266-271
118. Frostell C., Fratacci M.D., Wain J.C., Jones R., and Zapol W.M. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 83 (1991) 2038-2047
119. Bloch K.D., Ichinose F., Roberts Jr. J.D., and Zapol W.M. Inhaled NO as a therapeutic agent. Cardiovasc Res 75 (2007) 339-348
120. Ichinose F., Roberts Jr. J.D., and Zapol W.M. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation 109 (2004) 3106-3111
121. Endo G.J., Kojima K., Nakamura K., Matsuzaki Y., and Onitsuka T. Nitric oxide inhalation prompts weaning from the right ventricular assist device: evaluation under continuous-flow biventricular assistance. J Thorac Cardiovasc Surg 124 (2002) 739-749
122. Koelling T.M., Kirmse M., Di Salvo T.G., Dec G.W., Zapol W.M., and Semigran M.J. Inhaled nitric oxide improves exercise capacity in patients with severe heart failure and right ventricular dysfunction. Am J Cardiol 81 (1998) 1494-1497
123. Ardehali A., Hughes K., Sadeghi A., et al. Inhaled nitric oxide for pulmonary hypertension after heart transplantation. Transplantation 72 (2001) 638-641
124. Girard C., Durand P.G., Vedrinne C., et al. Case 4-1993. Inhaled nitric oxide for right ventricular failure after heart transplantation. J Cardiothorac Vasc Anesth 7 (1993) 481-485
125. Rich G.F., Murphy Jr. G.D., Roos C.M., and Johns R.A. Inhaled nitric oxide. Selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 78 (1993) 1028-1035
126. Fullerton D.A., Jones S.D., Jaggers J., Piedalue F., Grover F.L., and McIntyre Jr. R.C. Effective control of pulmonary vascular resistance with inhaled nitric oxide after cardiac operation. J Thorac Cardiovasc Surg 111 (1996) 753-762 discussion 762-3
127. Beck J.R., Mongero L.B., Kroslowitz R.M., et al. Inhaled nitric oxide improves hemodynamics in patients with acute pulmonary hypertension after high-risk cardiac surgery. Perfusion 14 (1999) 37-42
128. Argenziano M., Choudhri A.F., Moazami N., et al. Randomized, double-blind trial of inhaled nitric oxide in LVAD recipients with pulmonary hypertension. Ann Thorac Surg 65 (1998) 340-345
129. Miller O.I., Tang S.F., Keech A., and Celermajer D.S. Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 346 (1995) 51-52
130. Bocchi E.A., Bacal F., Auler Junior J.O., Carmone M.J., Bellotti G., and Pileggi F. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 74 (1994) 70-72
131. Cheitlin M.D., Hutter Jr. A.M., Brindis R.G., et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 33 (1999) 273-282
132. Parker J.D., Bart B.A., Webb D.J., et al. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial. Crit Care Med 35 (2007) 1863-1868
133. Stehlik J., and Movsesian M.A. Combined use of PDE5 inhibitors and nitrates in the treatment of pulmonary arterial hypertension in patients with heart failure. J Card Fail 15 (2009) 31-34
134. Kihara S., Kawai A., Fukuda T., et al. Effects of milrinone for right ventricular failure after left ventricular assist device implantation. Heart Vessels 16 (2002) 69-71
135. Haraldsson s A., Kieler-Jensen N., and Ricksten S.E. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth Analg 93 (2001) 1439-1445
136. O'Dell K.M., Kalus J.S., Kucukarslan S., and Czerska B. Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. Am J Health Syst Pharm 62 (2005) 606-609
137. Martin J., Siegenthaler M.P., Friesewinkel O., et al. Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study. Eur J Cardiothorac Surg 25 (2004) 971-977
138. Adamson R.M., Dembitsky W.P., Jaski B.E., et al. Left ventricular assist device support of medically unresponsive pulmonary hypertension and aortic insufficiency. ASAIO J 43 (1997) 365-369
139. Petrofski J.A., Hoopes C.W., Bashore T.M., Russell S.D., and Milano C.A. Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congenital heart disease. Ann Thorac Surg 75 (2003) 1005-1007
140. Al-Khaldi A., Ergina P., DeVarennes B., Lachappelle K., and Cecere R. Left ventricular unloading in a patient with end-stage cardiomyopathy and medically unresponsive pulmonary hypertension. Artif Organs 28 (2004) 158-160
141. Andrea G., Giuseppe B., Tiziano C., Maria F., and Ettore V. Is fixed severe pulmonary hypertension still a contraindication to heart transplant in the modern era of mechanical circulatory support? A review. J Cardiovasc Med (Hagerstown) 9 (2008) 1059-1062
142. Zimpfer D., Zrunek P., Roethy W., et al. Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 133 (2007) 689-695
143. Etz C.D., Welp H.A., Tjan T.D., et al. Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices. Ann Thorac Surg 83 (2007) 1697-1705
144. Liden H., Haraldsson A., Ricksten S.E., Kjellman U., and Wiklund L. Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance?. Eur J Cardiothorac Surg (2009)
145. Bleasdale R.A., Banner N.R., Anyanwu A.C., Mitchell A.G., Khaghani A., and Yacoub M.H. Determinants of outcome after heterotopic heart transplantation. J Heart Lung Transplant 21 (2002) 867-873
146. Pagano D., Townend J.N., Horton R., Smith C., Clutton-Brock T., and Bonser R.S. A comparison of inhaled nitric oxide with intravenous vasodilators in the assessment of pulmonary haemodynamics prior to cardiac transplantation. Eur J Cardiothorac Surg 10 (1996) 1120-1126
147. Murali S., Uretsky B.F., Armitage J.M., et al. Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant 11 (1992) 716-723
148. Wasler A., Iberer F., Tscheliessnigg K.H., Auer T., and Petutschnigg B. Prostaglandin E1 in the pretransplantation period in patients with pulmonary hypertension. J Heart Lung Transplant 12 (1993) 884
149. Trautnitz M., Pehlivanli S., Behr J., et al. [Pharmacological testing of the reversibility of increased pulmonary vascular resistance before heart transplantation with prostaglandin I2 (prostacyclin)]. Z Kardiol 88 (1999) 133-140
150. de Freitas Jr. A.F., Bacal F., Oliveira Jde Jr. L., et al. Impact of sublingual sildenafil on pulmonary hypertension in patients with heart failure. Arq Bras Cardiol 92 (2009) 116-126
151. Mahajan A., Shabanie A., Varshney S.M., Marijic J., and Sopher M.J. Inhaled nitric oxide in the preoperative evaluation of pulmonary hypertension in heart transplant candidates. J Cardiothorac Vasc Anesth 21 (2007) 51-56
152. Fojon S., Fernandez-Gonzalez C., Sanchez-Andrade J., et al. Inhaled nitric oxide through a noninvasive ventilation device to assess reversibility of pulmonary hypertension in selecting recipients for heart transplant. Transplant Proc 37 (2005) 4028-4030
153. Loh E., Stamler J.S., Hare J.M., Loscalzo J., and Colucci W.S. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 90 (1994) 2780-2785
154. ENABLE. Effects of the Endothelin Receptor Antagonist Bosentan on the Morbidity and Mortality in Patients with Chronic Heart Failure Cardiosource 2002;Clinical trials.
155. Kaluski E., Kobrin I., Zimlichman R., et al. RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study. J Am Coll Cardiol 41 (2003) 204-210
156. Salzberg S.P., Lachat M.L., von Harbou K., Zund G., and Turina M.I. Normalization of high pulmonary vascular resistance with LVAD support in heart transplantation candidates. Eur J Cardiothorac Surg 27 (2005) 222-225
157. Gallagher R.C., Kormos R.L., Gasior T., Murali S., Griffith B.P., and Hardesty R.L. Univentricular support results in reduction of pulmonary resistance and improved right ventricular function. ASAIO Trans 37 (1991) M287-M288
158. Nguyen D.Q., Ormaza S., Miller L.W., et al. Left ventricular assist device support for medically unresponsive pulmonary hypertension from left ventricular failure. J Heart Lung Transplant 20 (2001) 190
159. Smedira N.G., Massad M.G., Navia J., et al. Pulmonary hypertension is not a risk factor for RVAD use and death after left ventricular assist system support. ASAIO J 42 (1996) M733-M735